other material
confidence high
sentiment positive
materiality 0.75
Trevi's Haduvio meets Phase 2a RIVER primary endpoint; 57% placebo-adjusted cough reduction
Trevi Therapeutics, Inc.
- Primary endpoint: 67% reduction from baseline in 24-hour cough frequency; 57% placebo-adjusted (p<0.0001).
- 84% of Haduvio patients had ≥30% reduction vs 29% placebo; early response at Day 7 (27 mg BID).
- Severe cough subgroup (20+ coughs/hr): 66% reduction; moderate (10-19/hr): 68% reduction (p<0.0001).
- Safety profile consistent with prior Haduvio trials; no treatment-emergent serious adverse events.
- Trevi plans to discuss results with FDA and initiate next study after FDA input.